Innovative therapeutic system of vector action for the treatment of a wide range of malignant neoplasms, in particular the breast.
PeFagTal
®
BioTechnology, established on 2015, devoted its activities to one of the crucial challengers of the XXI century - the study of oncological diseases and the development of drugs that can treat cancer.
According to the forecast of the International Agency for Research on Cancer (IARC WHO), by 2035, the incidence of malignant neoplasms will increase by 42% and amount to 27.4 million new cases per year. One of the directions of development of antitumor therapy is the creation of nanosomal drug delivery systems (NDDS). The National Cancer Institute of the USA (NSI US) has been implementing a program to support the development of nanosomal drugs in oncology"Cancer Nanotechnology plan" since 2004. There are similar programs in the European Union and Japan. The creation of innovative drugs for the treatment of oncological diseases (including those based on NDS technologies) is an important part of the development strategy of the pharmaceutical industry.
According to the forecast of the International Agency for Research on Cancer (IARC WHO), by 2035, the incidence of malignant neoplasms will increase by 42% and amount to 27.4 million new cases per year. One of the directions of development of antitumor therapy is the creation of nanosomal drug delivery systems (NDDS). The National Cancer Institute of the USA (NSI US) has been implementing a program to support the development of nanosomal drugs in oncology"Cancer Nanotechnology plan" since 2004. There are similar programs in the European Union and Japan. The creation of innovative drugs for the treatment of oncological diseases (including those based on NDS technologies) is an important part of the development strategy of the pharmaceutical industry.
®
About PeFagTal
The active substance of the therapeutic system is thallium salts, which have an antitumor effect.
The virus-like particle, based on the capsid protein of the bacteriophage MS2 is a nanoscale transport capsule - a means of delivery.
The virus-like particle, based on the capsid protein of the bacteriophage MS2 is a nanoscale transport capsule - a means of delivery.
IRDG peptides on the surface of the bacteriophage capsule provide binding to the integrin ανβ3 in the endothelium of tumor vessels – due to this mechanism, the vector (directed, targeted) action of the therapeutic system on tumor tissue is realized.
Results of preclinical studies of PeFagTal®
When conducting preclinical studies of PeFagTal®, a comparative analysis of the effectiveness with doxorubicin (intraperitoneal administration, a dose of 5 mcg / kg) showed similar cytotoxic effects, but the survival rate of mice under the action of the drug PeFagTal® does not decrease (see figure), unlike doxorubicin, and also the average weight of mice treated with doxorubicin is 28% lower than that of mice treated with PeFagTal® in all studied dosages, figure below.
About R&D
Our Contacts
Ask your question or you can call us
in a phone number below
in a phone number below
+998 90 902 20 01
projects@pefagtal.com
projects@pefagtal.com
Tashkent,Uzbekistan branch of BioTechnology
Kichik Beshagach st., 27, Tashkent, Uzbekistan
Representative in UAE
S M Management Consultancies Co.
Address: IBN BATUTA Gate Offices
Business Center, Office 57, 11th Floor,
PO Box 72800, Dubai, UAE
T: +971 50 154 65 71
Kichik Beshagach st., 27, Tashkent, Uzbekistan
Representative in UAE
S M Management Consultancies Co.
Address: IBN BATUTA Gate Offices
Business Center, Office 57, 11th Floor,
PO Box 72800, Dubai, UAE
T: +971 50 154 65 71